We measured the survival of EBV-positive B-cells and EBV-positive gastric carcinoma cells in which the levels of IPO7 were demonstrably reduced following mutagenesis by treatment with CRISPR/Cas9 (Figures 3C, 4C) and found no effect on their survival. The gene discussed is IPO7; the disease is gastric carcinoma.